Patent intelligence · US
US 7560105
Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses
Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses
Patent details — US 7560105
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 14, 2009
- Expiration
- Jul 9, 2029
- Applicant
- Leids Universitair Medisch Centrum
- Claims
- 43
- CPC classes
- A61K, A61K2035/122, A61K40/19, A61K40/24
Quick answer
US 7560105 (Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses) is held by Leids Universitair Medisch Centrum. Status: granted. Granted Jul 14, 2009. Expires Jul 9, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Leids Universitair Medisch Centrum
- Grant date
- Expiration
- Claims
- 43
- CPC classes
- A61K, A61K2035/122, A61K40/19, A61K40/24, A61K40/4215, A61K40/4262
More from Leids Universitair Medisch Centrum
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 7560105?
US 7560105 (Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses) is held by Leids Universitair Medisch Centrum. Status: granted. Granted Jul 14, 2009. Expires Jul 9, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7560105?
Leids Universitair Medisch Centrum is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 7560105 expire?
Our index shows an expiration date of Jul 9, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.